More Is Not More: Hepcidin and the Counterintuitive Science of Iron Dosing

In my last post on donor iron deficiency, I buried the most interesting part.

Most of the piece covered what the field has established: donation depletes iron, ferritin screening is underutilized, the HEIRS and STRIDE trials make a reasonable case for supplementation, and the AABB has recommendations in place. All of that holds. But near the end, almost as a footnote, I mentioned that the original HEIRS trial used daily iron dosing — and that subsequent evidence suggests daily dosing may actually inhibit absorption by triggering the release of hepcidin.

I've been thinking about that footnote ever since. It deserves more than a footnote.

A Brief Introduction to Your Iron Gatekeeper

Hepcidin is a small peptide hormone made by the liver, and its job is to regulate how much iron enters circulation. When iron stores are adequate, hepcidin is secreted, binds to ferroportin — the channel that exports iron from cells into the bloodstream — and shuts the door. When stores are low, hepcidin falls and the door opens. It is an elegant feedback loop, and under normal circumstances it works well.

What makes hepcidin relevant to donor supplementation is a less intuitive property: it also responds acutely to oral iron ingestion. A single dose of 60 mg or more of elemental iron — roughly what you find in a standard over-the-counter supplement — triggers a hepcidin spike that sets in within hours and persists for approximately 24 hours before returning to baseline. While hepcidin is elevated, absorption from any subsequent dose is meaningfully suppressed.

The implication for how we advise donors to supplement follows directly from this.

The Problem With 'Take Iron Daily'

The instinct to recommend daily iron supplementation is understandable. More doses, more iron in, faster repletion. It is the same logic that leads to split dosing — take it twice a day to maximize the total amount ingested. Both approaches are intuitive. Both are, at least partially, counterproductive.

A 2015 study by Moretti and colleagues, published in Blood, was among the first to characterize this effect in humans. They showed that a morning iron supplement triggers sufficient hepcidin elevation to reduce absorption from a dose given later the same day — and that the response persists into the following morning. Split dosing compounded the problem: dividing the daily dose produced higher hepcidin and lower fractional absorption per dose, not better total uptake.

The 2017 Stoffel et al. trial in Lancet Haematology tested the logical alternative prospectively. Women randomized to alternate-day supplementation absorbed significantly more iron — both in fractional terms (21.8% vs. 16.3%) and in total — compared to those taking supplements daily. Allowing hepcidin to return to baseline between doses improved the efficiency of each one. Subsequent work confirmed that morning timing matters too: hepcidin follows a circadian pattern and is lower in the morning, making that the optimal window before the post-dose spike closes the door again.

The practical upshot is that a donor who dutifully takes iron every morning may be absorbing less than one who takes the same dose every other morning. The body's own regulatory response is working against the intervention.

What the Data Don't Yet Tell Us

The alternate-day evidence is compelling, but almost none of it was generated in blood donor populations specifically. Most studies enrolled iron-depleted or iron-deficient women — a related but not identical context. Donors vary considerably in baseline iron status, sex, age, donation frequency, and the degree of deficiency at the time of supplementation. Whether the absorption advantage of alternate-day dosing holds consistently across this range is not yet established.

The 2024 meta-analysis of daily versus alternate-day iron dosing added a useful wrinkle: baseline inflammation appears to modulate the benefit. Elevated hepcidin from inflammatory states may blunt the absorption advantage of spacing doses, since the favorable window is already partially closed before the first pill is swallowed. This is not a fringe concern in a donor population that includes people with subclinical inflammatory conditions.

The dose question is also genuinely unresolved. HEIRS used daily supplementation; we now know that was suboptimal from an absorption standpoint. The alternate-day studies suggest that doubling the per-dose amount on an alternate schedule can achieve comparable or greater total iron uptake — but this has not been validated prospectively in donors. We are, in effect, extrapolating from better-designed absorption studies to a population that hasn't been directly studied under the revised paradigm.

And then there is the infection question I raised in the earlier post. Oral iron has been shown to acutely elevate bacterial growth in human serum in iron-sufficient subjects. Whether this translates to iron-deficient donors — in whom the physiologic context is substantially different — remains unknown. No donor supplementation trial to date has tracked infection as an outcome. That gap is worth sitting with.

Where This Leaves Us

The case for addressing donor iron deficiency is solid. The case for doing it thoughtfully — rather than defaulting to daily supplementation because it seems like the obvious approach — is getting stronger.

Hepcidin is not a curiosity. It is a central regulator of iron homeostasis, and it does not stop working just because we want our donors to replete faster. Any supplementation strategy that ignores it is, at minimum, less efficient than it could be, and possibly counterproductive at the margins.

The AABB recommendations provide a reasonable framework. What they do not yet specify — with good evidence behind them — is the optimal schedule. Alternate-day morning dosing is the best current answer from the absorption literature. Whether that translates directly to the donor context, and at what dose, is work that still needs doing.

In the meantime, it seems worth updating the footnote.